Humanetics Corporation presented updates on the progress of BIO 300, an orally administered drug designed to prevent radiation toxicity in military personnel. The presentation was made at the 2024 Military Health System Research Symposium.
BIO 300 was initially developed as a radioprotectant by the Armed Forces Radiobiology Research Institute. Humanetics holds an exclusive license for its advanced development and commercialization. Ongoing collaborations with the Department of Defense aim to create an oral drug that warfighters can take to shield themselves from the effects of radiation exposure in radiological or nuclear events.
Research findings presented at the symposium demonstrate that BIO 300 is among the most advanced medical countermeasures currently under development for acute radiation syndrome (ARS). The development of such countermeasures is crucial given the elevated threat of nuclear or radiological occurrences in the current geopolitical climate.
Beyond military applications, BIO 300 is being investigated in phase 2 clinical trials for its potential to prevent tissue damage caused by cancer radiotherapy and reduce inflammatory lung injury in conditions like COVID-19 and Idiopathic Pulmonary Fibrosis.
The research has received funding from the US Department of Defense’s Congressionally Directed Medical Research Program and the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense. The views presented in the research do not necessarily represent the official policies or positions of the Department of Defense or the US Government.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
